Darren Hargrave
- Genetics top 0.1%
- Glioma Diagnosis and Treatment 112
- Neurology top 0.5%
- Neuroblastoma Research and Treatments 55
- Neurofibromatosis and Schwannoma Cases 17
- Cancer Research top 2%
- Oncology top 5%
- Molecular Biology top 5%
- Melanoma and MAPK Pathways 10
- Chromatin Remodeling and Cancer 9
-
- Meningioma and schwannoma management 23
-
- Childhood Cancer Survivors' Quality of Life 16
-
- Brain Metastases and Treatment 12
- Co-authors
- Éric BouffetUte BartelsChris JonesDorine A. BaxLara PerrymanUri TaboriBirgit GeoergerRui Manuel Reis
- Cited by
- GeneticsNeurologyCancer Research
- Journals
- New England Journal of Medicine (1 paper)The Lancet (1 paper)Journal of Clinical Oncology (27 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Darren Hargrave
172 papers receiving 5.5k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Genetics 3.3k
- Neurology 2.1k
- Cancer Research 687
- Oncology 779
- Molecular Biology 1.8k
Countries citing papers authored by Darren Hargrave
This map shows the geographic impact of Darren Hargrave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren Hargrave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren Hargrave more than expected).
Fields of papers citing papers by Darren Hargrave
This network shows the impact of papers produced by Darren Hargrave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren Hargrave. The network helps show where Darren Hargrave may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Darren Hargrave, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 4 | |
| 4 | 2023 | 1 | |
| 5 | Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutationsbreakdown → | 2023 | 125 |
| 6 | 2022 | 11 | |
| 7 | 2021 | 11 | |
| 8 | 2021 | 13 | |
| 9 | 2021 | 9 | |
| 10 | 2020 | 1 | |
| 11 | 2019 | 3 | |
| 12 | A 7-Year Update Report of a National, Interdisciplinary Endeavour to Improve Outcomes for Children and Young People Under 19 Years of Age with Hypothalamic Pituitary Axis Tumours (HPAT) Using Multi-site Video Conferencing | 2018 | 2 |
| 13 | 2016 | 23 | |
| 14 | 2014 | 39 | |
| 15 | 2013 | 226 | |
| 16 | A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL SONIDEGIB (LDE225) VERSUS TEMOZOLOMIDE IN PATIENTS WITH HEDGEHOG PATHWAY-ACTIVATED RELAPSED MEDULLOBLASTOMA | 2013 | 5 |
| 17 | 2012 | 143 | |
| 18 | 2011 | 41 | |
| 19 | 2010 | 110 | |
| 20 | 2009 | 71 |
About Darren Hargrave
Darren Hargrave is a scholar working on Genetics, Neurology and Pediatrics, Perinatology and Child Health, having authored 187 papers that have together received 5.5k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (112 papers), Neuroblastoma Research and Treatments (55 papers), Meningioma and schwannoma management (23 papers), Neurofibromatosis and Schwannoma Cases (17 papers), Childhood Cancer Survivors' Quality of Life (16 papers), Brain Metastases and Treatment (12 papers), Melanoma and MAPK Pathways (10 papers) and Chromatin Remodeling and Cancer (9 papers). The work is most often cited by research in Genetics (3.3k citations), Neurology (2.1k citations) and Cancer Research (687 citations). Darren Hargrave has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Éric Bouffet, Ute Bartels, Chris Jones, Dorine A. Bax, Lara Perryman, Uri Tabori, Birgit Geoerger, Rui Manuel Reis, Alberto Broniscer and Isabelle Aerts. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.